Comparative efficacy of long-acting muscarinic antagonists in preventing COPD exacerbations: A network meta-analysis and meta-regression

Therapeutic Advances in Respiratory Disease

Volumn 9, Issue 1, 2015, Pages 3-15

  Oba, Yuji ^a   Lone, Nazir A ^b  

^a University of Missouri   (United States)

^b BASSETT MEDICAL CENTER   (United States)

Author keywords

aclidinium bromide; glycopyrronium; tiotropium

Indexed keywords

ACLIDINIUM BROMIDE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; GLYCOPYRRONIUM BROMIDE; MUSCARINIC RECEPTOR BLOCKING AGENT; BRONCHODILATING AGENT;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPARATIVE STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION; DISEASE COURSE; DRUG EFFECTS; LUNG; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; TIME; TREATMENT OUTCOME;

BRONCHODILATOR AGENTS; DISEASE PROGRESSION; HUMANS; LUNG; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84922371459     PISSN: 17534658     EISSN: 17534666     Source Type: Journal    
DOI: 10.1177/1753465814565624     Document Type: Article

References (47)

1. Ambrosino N. Foglio K. Balzano G. Paggiaro P. Lessi P. Kesten S. (2008) Tiotropium and exercise training in COPD patients: effects on dyspnea and exercise tolerance. Int J Chron Obstruct Pulmon Dis 3: 771–780.
2. Barr R. Bourbeau J. Camargo C. Ram F. (2006) Tiotropium for stable chronic obstructive pulmonary disease: A meta-analysis. Thorax 61: 854–862.
3. Bateman E. Singh D. Smith D. Disse B. Towse L. Massey D. (2010a) Efficacy and safety of tiotropium Respimat SMI in COPD in two 1-year randomized studies. Int J Chron Obstruct Pulmon Dis 5: 197–208.
4. Bateman E. Tashkin D. Siafakas N. Dahl R. Towse L. Massey D. (2010b) A one-year trial of tiotropium Respimat plus usual therapy in COPD patients. Respir Med 104: 1460–1472.
5. Bateman E. Ferguson G. Barnes N. Gallagher N. Green Y. Henley M. (2013) Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J 42: 1484–1494.
6. Beeh K. Beier J. Buhl R. Stark-Lorenzen P. Gerken F. Metzdorf N. (2006) [Efficacy of tiotropium bromide (Spiriva) in patients with chronic-obstructive pulmonary disease (COPD) of different severities]. Pneumologie 60: 341–346.
7. Brusasco V. Hodder R. Miravitlles M. Korducki L. Towse L. Kesten S. (2003) Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 58: 399–404.
8. Casaburi R. Mahler D. Jones P. Wanner A. San P. ZuWallack R. (2002) A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 19: 217–224.
9. Chan C. Maltais F. Sigouin C. Haddon J. Ford G. (2007) A randomized controlled trial to assess the efficacy of tiotropium in Canadian patients with chronic obstructive pulmonary disease. Can Respir J 14: 465–472.
10. Chapman K. Beeh K. Beier J. Bateman E. D–Urzo A. Nutbrown R. (2014) A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study. BMC Pulm Med 14: 4.
11. Cooper C. Celli B. Jardim J. Wise R. Legg D. Guo J. (2013) Treadmill endurance during 2-year treatment with tiotropium in patients with COPD: a randomized trial. Chest 144: 490–497.
12. Cope S. Zhang J. Williams J. Jansen J. (2012) Efficacy of once-daily indacaterol 75 mug relative to alternative bronchodilators in COPD: a study level and a patient level network meta-analysis. BMC Pulm Med 12: 29.
13. Dalal A. Christensen L. Liu F. Riedel A. (2010) Direct costs of chronic obstructive pulmonary disease among managed care patients. Int J Chron Obstruct Pulmon Dis 5: 341–349.
14. Dias S. Sutton A. Welton N. Ades A. (2013a) Evidence synthesis for decision making 3: heterogeneity'subgroups, meta-regression, bias, and bias-adjustment. Med Decis Making 33: 618–640.
15. Dias S. Welton N. Sutton A. Caldwell D. Lu G. Ades A. (2013b) Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials. Med Decis Making 33: 641–656.
16. Donohue J. Fogarty C. Lotvall J. Mahler D. Worth H. Yorgancioglu A. (2010) Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 182: 155–162.
17. D–Urzo A. Ferguson G. van Noord J. Hirata K. Martin C. Horton R. (2011) Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir Res 12: 156.
18. Dusser D. Bravo M. Iacono P. (2006) The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur Respir J 27: 547–555.
19. Feemster L. Au D. (2014) Penalizing hospitals for chronic obstructive pulmonary disease readmissions. Am J Respir Crit Care Med 189: 634–639.
20. Freeman D. Lee A. Price D. (2007) Efficacy and safety of tiotropium in COPD patients in primary care–the SPiRiva Usual CarE (SPRUCE) study. Respir Res 8: 45.
21. Friedman M. Serby C. Menjoge S. Wilson J. Hilleman D. Witek T. Jr (1999) Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD. Chest 115: 635–641.
22. Guevara J. Berlin J. Wolf F. (2004) Meta-analytic methods for pooling rates when follow-up duration varies: a case study. BMC Med Res Methodol 4: 17.
23. Jones P. Rennard S. Agusti A. Chanez P. Magnussen H. Fabbri L. (2011) Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease. Respir Res 12: 55.
24. Jones P. Singh D. Bateman E. Agusti A. Lamarca R. de Miquel G. (2012) Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. Eur Respir J 40: 830–836.
25. Karabis A. Lindner L. Mocarski M. Huisman E. Greening A. (2013). Comparative efficacy of aclidinium versus glycopyrronium and tiotropium, as maintenance treatment of moderate to severe COPD patients: a systematic review and network meta-analysis. Int J Chron Obstruct Pulmon Dis 8: 405–423.
26. Karner C. Cates C. (2012) Long-acting beta(2)-agonist in addition to tiotropium versus either tiotropium or long-acting beta(2)-agonist alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 4: CD008989.
27. Karner C. Chong J. Poole P. (2012) Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 7: CD009285.
28. Kerwin E. Hebert J. Gallagher N. Martin C. Overend T. Alagappan V. (2012a) Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur Respir J 40: 1106–1114.
29. Kerwin E. D–Urzo A. Gelb A. Lakkis H. Garcia Gil E. Caracta C. (2012b) Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD 9: 90–101.
30. Lu G. Ades A. (2004) Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 23: 3105–3124.
31. Niewoehner D. Rice K. Cote C. Paulson D. Cooper J. Jr Korducki L. (2005) Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med 143: 317–326.
32. Novartis (2012) Long Term Safety and Tolerability of NVA237 Versus Tiotropium in Japanese Patients (GLOW4). ClinicalTrials.gov identifier: NCT01119937. Available at: http://clinicaltrials.gov/ct2/show/results/NCT01119937 ( accessed 29 October 2014).
33. Oba Y. (2007) Cost-effectiveness of long-acting bronchodilators for chronic obstructive pulmonary disease. Mayo Clin Proc 82: 575–582.
34. Powrie D. Wilkinson T. Donaldson G. Jones P. Scrine K. Viel K. (2007) Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD. Eur Respir J 30: 472–478.
35. Rennard S. Scanlon P. Ferguson G. Rekeda L. Maurer B. Garcia Gil E. (2013) ACCORD COPD II: a randomized clinical trial to evaluate the 12-week efficacy and safety of twice-daily aclidinium bromide in chronic obstructive pulmonary disease patients. Clin Drug Investig 33: 893–904.
36. Salanti G. Ades A. Ioannidis J. (2011) Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 64: 163–171.
37. Spiegelhalter D. Best N. Carlin B. Van Der Linde A. (2002) Bayesian measures of model complexity and fit. J R Stat Soc Series B Stat Methodol 64: 583–639.
38. Suissa S. Dell–Aniello S. Ernst P. (2012) Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax 67: 957–963.
39. Tashkin D. Celli B. Senn S. Burkhart D. Kesten S. Menjoge S. (2008) A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 359: 1543–1554.
40. Toft N. Innocent G. Gettinby G. Reid S. (2007) Assessing the convergence of Markov Chain Monte Carlo methods: an example from evaluation of diagnostic tests in absence of a gold standard. Prev Vet Med 79: 244–256.
41. Tonnel A. Perez T. Grosbois J. Verkindre C. Bravo M. Brun M. (2008) Effect of tiotropium on health-related quality of life as a primary efficacy endpoint in COPD. Int J Chron Obstruct Pulmon Dis 3: 301–310.
42. Ulrik C. (2012) Once-daily glycopyrronium bromide, a long-acting muscarinic antagonist, for chronic obstructive pulmonary disease: a systematic review of clinical benefit. Int J Chron Obstruct Pulmon Dis 7: 673–678.
43. Vestbo J. Hurd S. Agusti A. Jones P. Vogelmeier C. Anzueto A. (2013) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 187: 347–365.
44. Vogelmeier C. Kardos P. Harari S. Gans S. Stenglein S. Thirlwell J. (2008) Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study. Respir Med 102: 1511–1520.
45. Wedzicha J. Decramer M. Ficker J. Niewoehner D. Sandstrom T. Taylor A. (2013) Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med 1: 199–209.
46. WHO (2004) World Health Organization Chronic respiratory diseases. Global surveillance, prevention and control of chronic respiratory diseases. Chronic obstructive pulmonary disease. http://www.who.int/respiratory/copd/en ( accessed 29 October 2014).
47. Wise R. Anzueto A. Cotton D. Dahl R. Devins T. Disse B. (2013) Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med 369: 1491–1501.